Ignite Creation Date:
2025-12-25 @ 3:52 AM
Ignite Modification Date:
2025-12-26 @ 2:41 AM
Study NCT ID:
NCT06082102
Status:
RECRUITING
Last Update Posted:
2025-09-15
First Post:
2023-10-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-19
Start Date Type:
ACTUAL
Primary Completion Date:
2028-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-02-25
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-08
First Submit QC Date:
None
Study First Post Date:
2023-10-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-12
Last Update Post Date:
2025-09-15
Last Update Post Date Type:
ESTIMATED